The Rheumatology Nurses Society and Haymarket Medical Education present: Immunotherapy-Induced Rheumatic Diseases: Managing the Intersection of Rheumatology and Oncology
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time. A certificate of completion will be generated on the website where the course was completed and will not appear in your RNS profile.
While the discovery of the immune checkpoint inhibitor (ICI) drug class has led to improved outcomes for many patients with various types of cancers, these agents are associated with a number of immune-related adverse events (irAEs) that can potentially affect any system in the body. Consequently, rheumatologic irAEs are being seen at an increased rate in clinical practice.
Unfortunately, many clinical trials that have published toxicity data do not report rheumatic irAEs, do not provide clinical descriptions of these events, or report only high-grade AEs. As a result, the true epidemiology of such events and a consistent profile of clinical features remain unclear.
As a result of anticipated exponential growth in the use of ICIs to manage an increasingly long list of cancers, clinicians can expect to encounter increasing numbers of patients with rheumatic irAEs. To meet the educational needs of healthcare providers, this myCME Go video series convenes a leading oncologist and a rheumatologist to discuss the rheumatologic irAEs most commonly observed with ICI agents and how a guideline-driven, stepwise approach to managing these events can best be implemented among members of the collaborative care team.
Rheumatologists, rheumatology nurses, and NPs and PAs with a specialty in rheumatology
- Describe the currently approved ICIs, their indications, and their mechanisms of action (MOAs) and how these agents may cause side effects that present like rheumatic disease
- Recognize the distinct clinical features and grades of rheumatic irAEs and their long-term sequelae
- Implement a guideline-driven, stepwise approach to managing rheumatic irAEs
- Distinguish the need for conservative vs aggressive management and mitigate the risk for interrupted or prematurely discontinued immuno-oncology (IO) treatment
- Engage in collaborative clinical decision-making with colleagues in oncology and related specialties
ACCREDITED PROVIDER DISCLOSURE
The staff of Haymarket Medical Education and Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner of AKH Inc., Advancing Knowledge in Healthcare have no relevant financial relationships to disclose.
TYPE: CNE Contact Hour(s)
AKH Inc., Advancing Knowledge in Healthcare is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.